- Home
- DAVE vs NRIX Comparison
DAVE vs NRIX Comparison
Compare DAVE & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAVE
- NRIX
- Stock Information
- Founded
- DAVE 2017
- NRIX 2009
- Country
- DAVE United States
- NRIX United States
- Employees
- DAVE N/A
- NRIX N/A
- Industry
- DAVE Retail: Computer Software & Peripheral Equipment
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- DAVE Technology
- NRIX Health Care
- Exchange
- DAVE Nasdaq
- NRIX Nasdaq
- Market Cap
- DAVE 1.1B
- NRIX 1.1B
- IPO Year
- DAVE N/A
- NRIX 2020
- Fundamental
- Price
- DAVE $200.82
- NRIX $10.63
- Analyst Decision
- DAVE Strong Buy
- NRIX Strong Buy
- Analyst Count
- DAVE 7
- NRIX 17
- Target Price
- DAVE $169.71
- NRIX $30.71
- AVG Volume (30 Days)
- DAVE 618.3K
- NRIX 739.8K
- Earning Date
- DAVE 05-08-2025
- NRIX 07-10-2025
- Dividend Yield
- DAVE N/A
- NRIX N/A
- EPS Growth
- DAVE N/A
- NRIX N/A
- EPS
- DAVE 3.70
- NRIX N/A
- Revenue
- DAVE $381,425,000.00
- NRIX $56,417,000.00
- Revenue This Year
- DAVE $34.79
- NRIX $15.43
- Revenue Next Year
- DAVE $16.48
- NRIX N/A
- P/E Ratio
- DAVE $54.28
- NRIX N/A
- Revenue Growth
- DAVE 39.31
- NRIX N/A
- 52 Week Low
- DAVE $28.31
- NRIX $8.18
- 52 Week High
- DAVE $220.34
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- DAVE 73.41
- NRIX 54.08
- Support Level
- DAVE $190.41
- NRIX $9.67
- Resistance Level
- DAVE $220.34
- NRIX $10.79
- Average True Range (ATR)
- DAVE 9.81
- NRIX 0.53
- MACD
- DAVE 0.76
- NRIX 0.16
- Stochastic Oscillator
- DAVE 62.70
- NRIX 89.61
About DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.